Related Experiment Video
Updated: Jul 11, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam--is it still an issue?
Olaf Penack1, Patricia Rempf, Barbara Graf
1Hematology and Oncology, Campus Benjamin Franklin, D-12200 Berlin, Germany. penacko@mskcc.org
Abstract:
We evaluated the impact of piperacillin/tazobactam (PT) therapy on galactomannan enzyme immunoassay (GEI) testing (Platelia; Bio-Rad, Marnes La Coquette, France). Galactomannan contents of PT batches were highly variable. We found that false-positive GEI results can be avoided by performance of blood sampling before PT administration and by using separate sites for blood sampling and for administration of antibiotics.
Insights
False-positive galactomannan enzyme immunoassay (GEI) results from piperacillin/tazobactam (PT) therapy can be prevented. Blood draws before PT administration and separate IV sites minimize interference, ensuring accurate diagnostic testing.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Diagnostic Immunology
Background:
- Piperacillin/tazobactam (PT) is a widely used antibiotic.
- Galactomannan enzyme immunoassay (GEI) is a key diagnostic test for invasive fungal infections.
- Potential interference of PT with GEI testing requires investigation.
Purpose of the Study:
- To assess the impact of piperacillin/tazobactam (PT) therapy on the accuracy of galactomannan enzyme immunoassay (GEI).
- To identify strategies for mitigating PT-related interference in GEI results.
Main Methods:
- Evaluation of galactomannan content in various PT batches.
- Analysis of GEI test results in relation to PT administration timing and site.
- Comparison of GEI results obtained with different blood sampling and antibiotic administration protocols.
Main Results:
- Significant variability in galactomannan content was observed across different PT batches.
- False-positive GEI results were associated with PT administration.
- Implementing blood sampling prior to PT administration and using separate administration sites effectively prevented false positives.
Conclusions:
- Piperacillin/tazobactam therapy can interfere with galactomannan enzyme immunoassay testing.
- Pre-administration blood sampling and distinct administration sites are crucial for accurate GEI results.
- These procedural adjustments are recommended to maintain the diagnostic utility of GEI in patients receiving PT.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Atypical Pneumonia
Pneumonia III: Complications and Assessment
Automated Microbial Diagnostics